beta-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure
| Autor: | Andrew J.S. Coats, Maria Giovanna Conti, Giulio Spinucci, Giuseppe Ambrosio, Alain Cohen-Solal, Adriano Murrone, Michael Böhm, Dirk J. van Veldhuisen, Flavio Mascagni, Luigi Tavazzi, Marcus Flather |
|---|---|
| Přispěvatelé: | Cardiovascular Centre (CVC), Cardiovasculair Centrum |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Male
MEDICAL PROGRESS medicine.medical_specialty ACUTE MYOCARDIAL-INFARCTION Heart disease Vasodilator Agents Adrenergic beta-Antagonists Myocardial Ischemia METOPROLOL Sudden death Nebivolol Coronary artery disease SUDDEN-DEATH Internal medicine medicine Humans Diseases of the circulatory (Cardiovascular) system Benzopyrans Myocardial infarction NITRIC-OXIDE SYNTHASE Aged Aged 80 and over Heart Failure CARVEDILOL Ejection fraction business.industry Unstable angina MORTALITY medicine.disease RANDOMIZED-TRIAL Treatment Outcome Ethanolamines Heart failure RC666-701 Cardiology CORONARY-ARTERY-DISEASE Female Epidemiologic Methods Cardiology and Cardiovascular Medicine business MERIT-HF medicine.drug |
| Zdroj: | Кардиоваскулярная терапия и профилактика, Vol 10, Iss 4, Pp 69-76 (2011) Heart, 97(3), 209-214. BMJ PUBLISHING GROUP Scopus-Elsevier Cardiovascular therapy and prevention, 10(4), 69-76 |
| ISSN: | 1468-201X 1355-6037 1728-8800 |
| Popis: | Aim. This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a β-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects on heart failure (HF), by reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. Material and methods. A double-blind, randomised, placebo-controlled, multicentre trial of nebivolol in 2128 elderly patients. For this analysis, data were extracted for 2128 elderly (≥70 years) HF patients in whom coronary artery disease (CAD) was the underlying aetiology (68,2 %; 717 placebo-treated patients and 735 assigned to nebivolol). The main endpoint was the composite of cardiac ischaemic events at 2 year follow-up: death/hospitalisation for myocardial infarction, unstable angina or sudden death, as originally identified in the case report form. Results. At follow-up, nebivolol treatment was associated with a one-third reduction in the risk of ischaemic events, the composite endpoint occurring in 15,9 % of placebo and 10,7 % of nebivolol-treated patients (HR 0,68; 95 % CI 0,51 to 0,90; p=0,008). This effect was independent of age, gender and ejection fraction. No difference in this composite endpoint was observed in the subgroup of patients of non-ischaemic aetiology. Conclusion. Nebivolol was effective in reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. The prevention of ischaemic events can be an additional beneficial effect of β-blockade in HF patients with underlying CAD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|